Research Analysts Set Expectations for FULC FY2030 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Stock analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Fulcrum Therapeutics in a report released on Tuesday, February 24th. HC Wainwright analyst A. Maldonado anticipates that the company will earn $2.71 per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Several other brokerages also recently weighed in on FULC. The Goldman Sachs Group reaffirmed a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Bank of America upped their price objective on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a report on Tuesday, December 9th. Stifel Nicolaus set a $25.00 target price on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $23.00 price objective (up from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Fulcrum Therapeutics Stock Performance

Shares of FULC opened at $8.73 on Wednesday. The stock has a market capitalization of $581.42 million, a P/E ratio of -7.40 and a beta of 3.19. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $15.74. The company’s fifty day moving average is $10.66 and its two-hundred day moving average is $9.47.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31).

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth $30,000. Meeder Asset Management Inc. acquired a new position in Fulcrum Therapeutics in the fourth quarter valued at $39,000. Quarry LP acquired a new stake in Fulcrum Therapeutics during the third quarter worth about $35,000. Persistent Asset Partners Ltd purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth about $75,000. Finally, Farther Finance Advisors LLC raised its holdings in Fulcrum Therapeutics by 108.3% in the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the sale, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares in the company, valued at approximately $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.00% of the company’s stock.

Fulcrum Therapeutics News Summary

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near-term loss forecasts across Q1–Q4 2026 (from about ($0.29) to ($0.28) per quarter) and raised FY2026 and FY2027 EPS (less negative), while reiterating a “Buy” rating and a $25 price target — a vote of confidence that supports upside if clinical/catalyst risk eases. MarketBeat FULC
• Positive Sentiment: Stifel published commentary saying Fulcrum’s recent share decline looks “overdone,” which may attract value-oriented buyers and provide short-term buying support. Stifel: Move Lower Overdone
• Positive Sentiment: HC Wainwright also published long-term upside forecasts (FY2030 EPS est. $2.71) that, together with the $25 target, highlight a multi-year recovery scenario if clinical programs and commercialization prospects succeed. MarketBeat FULC
• Neutral Sentiment: Fulcrum’s Q4 2025 results and earnings call largely met expectations (reported EPS approx. ($0.31) in line with consensus), so there were no large surprise beats to drive the stock higher — the quarter appears already priced in. Q4 2025 Earnings Call Summary
• Negative Sentiment: News that the stock “tumbled despite trial results” suggests the market was disappointed by the clinical readouts’ details, commercial implications, or guidance — that selling pressure appears to be the primary driver of today’s weakness. Investing.com: Stock Tumbles
• Negative Sentiment: HC Wainwright trimmed FY2028 and FY2029 EPS modestly (FY2028 to $0.87 from $0.94; FY2029 to $1.79 from $1.91), signaling slightly lower long-term revenue/profit expectations and tempering the bullish long-term case. MarketBeat FULC

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.